Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Belgium’s largest drugmaker UCB on Friday announced the successful closing of the sale, divestment and license of its mature neurology and allergy portfolio in China to CBC Group, Asia’s largest healthcare-focused asset management group, and Mubadala Investment Company for an enterprise value of $680 million, first announced earlier this year. 30 November 2024
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
All news
Biotechnology
It’s ASCO time again. The annual meeting of the American Society of Clinical Oncology (ASCO) is now almost upon us, with the event due to start in Chicago on Friday, May 31. 22 May 2019
Biotechnology
Less than a year after Japanese drugmaker Takeda’s Entyvio was approved in the company’s home country to treat ulcerative colitis, a further indication for the drug has been authorized. 22 May 2019
Biotechnology
Amgen today offered to acquire all the shares of its research partner, Copenhagen, Denmark-headquartered Nuevolution, for a consideration of 32.50 Swedish kronor in cash per share. 22 May 2019
Biotechnology
Shares in Array Biopharma closed 23% up on Tuesday and have now almost doubled in the year-to-date. 22 May 2019
Biotechnology
Russia’s first original drug for the treatment of severe psoriasis has been registered by one of the leading local drugmakers Biocad, according to the company. 22 May 2019
Biotechnology
US pharma giant Merck & Co announced yesterday that it will acquire privately held Peloton Therapeutics in a deal which could exceed $2.2 billion, and which would bring the company a late-stage kidney cancer candidate. 22 May 2019
Biotechnology
Merck & Co’s Keytruda (pembrolizumab) is the world’s top-selling immuno-oncology drug with approvals across 12 different cancer types, but even it cannot help in the metastatic triple-negative breast cancer (TNBC) setting. 21 May 2019
Biotechnology
At the ATS International Conference, the New Jersey, USA-based rare disease specialist Insmedmhas presented new data from the ongoing Phase III CONVERT study. 21 May 2019
Biotechnology
German biotech Evotec has bought Seattle, USA-based Just Biotherapeutics for up to $90 million, including performance-based payments over the next three years. The initial consideration upon closing is $ 60 million. 21 May 2019
Biotechnology
STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec, and Dizal Pharmaceutical, a biotechnology company, today announced a strategic partnership. 21 May 2019
Biotechnology
Ocular Therapeutix (Nasdaq: OCUL) late Monday announced top-line results from the first pivotal Phase III clinical trial of OTX-TP, which failed to meet primary endpoint but achieved statistically-significant reduction of intraocular pressure versus placebo. 21 May 2019
Biotechnology
As China is becoming an incubator for an increasing number of innovative biotech startups, multinationals are actively seeking potential novel assets to enrich their global pipelines, said speakers at the ChinaBio forum held recently in Shanghai, reports The Pharma Letter’s local correspondent Wang Fangqing. 20 May 2019
Biotechnology
Actelion, one of the Janssen companies of Johnson & Johnson, presented new data on its pulmonary drug yesterday at the American Thoracic Society (ATS) conference 2019. 20 May 2019
Biotechnology
Life sciences investment trust Syncona has set up a new cell therapy company. 20 May 2019
Biotechnology
Belgian biopharma UCB started the week by announcing that the US Food and Drug Administration (FDA) approval of Nayzilam (midazolam) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy. 20 May 2019
Biotechnology
Actelion, the Swiss biotech firm acquired by Johnson & Johnson’s Janssen unit in a $30 billion deal in 2017, has entered into a collaboration with UK-based Owlstone Medical. 20 May 2019
Biotechnology
When it comes to long-term investment in pharma stocks, looking at pipeline assets at a pre-clinical or early clinical stage gives as good a clue as any as to where the value lies. 17 May 2019
Biotechnology
A draft issued on March 29 by China’s National Health Commission (CNHC), which regulates hospitals in China, allows qualified 3 Jia ( meaning top-level) public hospitals to develop and commercialize somatic cell therapies within their own hospitals. 17 May 2019
Biotechnology
USA-based Celgene has won European approval for two new triplet regimens based on Revlimid (lenalidomide) and Imnovid (pomalidomide). 17 May 2019
Biotechnology
New Jersey, USA-based Merck & Co has announced it will present 140 abstracts at the upcoming annual meeting of the Annual Society of Clinical Oncology (ASCO), including on the anti-PD-1 blockbuster Keytruda (pembrolizumab) and Lynparza (olaparib) - in over 25 types of cancer. 17 May 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze